US Stock MarketDetailed Quotes
PMN ProMIS Neurosciences
- 1.270
- +0.180+16.51%
Close Oct 31 16:00 ET
- 1.200
- -0.070-5.51%
Post 19:32 ET
37.95MMarket Cap-2351P/E (TTM)
1.570High1.000Low850.65KVolume1.070Open1.090Pre Close1.11MTurnover6.18%Turnover RatioLossP/E (Static)29.89MShares3.10052wk High-16.71P/B17.48MFloat Cap0.92052wk Low--Dividend TTM13.77MShs Float9.800Historical High--Div YieldTTM52.29%Amplitude0.920Historical Low1.308Avg Price1Lot Size
ProMIS Neurosciences Stock Forum
Sign in to post a comment
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on its lead product candidate, PMN310, at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data supports PMN310's potential as an Alzheimer's dise...
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on its lead product candidate, PMN310, at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data supports PMN310's potential as an Alzheimer's dise...
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
ProMIS Neurosciences Inc. (Nasdaq: PMN) presented preclinical data at the 2024 Alzheimer's Association International Conference (AAIC) supporting their novel approach to optimizing an Alzheimer's disease (AD) vaccine. The company's proprietary computational platform identified four AβO-restricte...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
ProMIS Neurosciences Inc. (Nasdaq: PMN) presented preclinical data at the 2024 Alzheimer's Association International Conference (AAIC) supporting their novel approach to optimizing an Alzheimer's disease (AD) vaccine. The company's proprietary computational platform identified four AβO-restricte...
2
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
▪️ProMIS Neurosciences (Nasdaq: PMN) has reported positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310 in healthy volunteers for Alzheimer's disease. The results showed:
▪️A favorable safety profile and tolerability across four ascending dose levels
▪️Dose-dependent levels of PMN310 antibody in cerebrospinal fluid (CSF)
Potenti...
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
▪️ProMIS Neurosciences (Nasdaq: PMN) has reported positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310 in healthy volunteers for Alzheimer's disease. The results showed:
▪️A favorable safety profile and tolerability across four ascending dose levels
▪️Dose-dependent levels of PMN310 antibody in cerebrospinal fluid (CSF)
Potenti...
3
6
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
1
$ProMIS Neurosciences (PMN.US)$ 100% to neg in 15 mins. that's a shame. had a bit of news. it could have at least held +25%. shame health-care stocks do this often
2
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Den the Dragon : very fast
Jaguar8 OP Den the Dragon : Quick pump and dump which I don’t touch